Literature DB >> 27157460

(18)F NaF PET/CT in the Assessment of Metastatic Bone Disease: Comparison with Specific PET Tracers.

Mohsen Beheshti1, Werner Langsteger.   

Abstract

The skeletal system is the third most common site of metastases after the lungs and liver, and 80% of all reported metastatic bone disease is in patients with breast and prostate cancer. At present there are an unprecedented number of novel molecular imaging agents potentially available for the assessment of bone metastases in different cancer. This review assesses the role of PET in the imaging of skeletal metastases, focusing on the specific PET tracers (fluorodeoxyglucose, choline derivatives, and so forth), in comparison with (18)F NaF as a nonspecific bone-seeking PET agent.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Year:  2012        PMID： 27157460     DOI： 10.1016/j.cpet.2012.04.002

Source DB:  PubMed          Journal:  PET Clin        ISSN： 1556-8598


  2 in total

Review 1.  Therapy assessment of bone metastatic disease in the era of 223radium.

Authors:  Elba Etchebehere; Ana Emilia Brito; Alireza Rezaee; Werner Langsteger; Mohsen Beheshti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-31       Impact factor: 9.236

Review 2.  Comparison of 18 F-NaF Imaging, 99m Tc-MDP Scintigraphy, and 18 F-FDG for Detecting Bone Metastases.

Authors:  Habibollah Dadgar; Nasim Norouzbeigi; Narges Jokar; Jafar Zareizadeh; Ali Gholamrezanezhad; Hojjat Ahmadzadehfar; Moloud Abbaszadeh; Majid Assadi
Journal:  World J Nucl Med       Date:  2022-04-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.